Description:

CALGB 40302 FOLLOW-UP SOLID TUMOR EVALUATION FORM NCT00390455 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F593450E-79E6-42E1-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F593450E-79E6-42E1-E034-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 1/8/15
  3. 6/8/15
Uploaded on:

June 8, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

CALGB_40302_FU_SOL_TUM_EVAL_FRM NCT00390455

INSTRUCTIONS: Complete and submit this form as required by the protocol. Information in the upper right box must be completed for this form to be accepted. For optimal accuracy use black ink.

Header
Are data amended
Patient demographics
Reporting Period
Method of Evaluation (**)
cm
Response Status at This Assessment, Target Lesion (s)
Non-target Lesion(s) Follow-up Evaluation
Are there any non-target lesions
Method of Evaluation (**)
F/U Response Status (Use response status codes below.)
Response Status at This Assessment, Non-Target Lesion (s)
New Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions documented since the baseline evaluation
Method of Evaluation (**)
Overall Response
Overall response (Combine Target, Non-Target, and New Lesions.)

Similar models